Baird initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $46 price target Dyne has become “dramatically more affordable” since the mid-September Duchenne muscular dystrophy update, and there’s “substantial upside” to the valuation on the DM-1 program alone, which is holding “clear blockbuster potential,” the analyst tells investors in a research note. The firm says the next data, coming in early January, should strengthen the case for the drug’s potential.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics initiated with an Outperform at RBC Capital
- Dyne Therapeutics Reveals Q3 Results and Trial Updates
- Dyne Therapeutics reports Q3 EPS (96c), consensus (71c)
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
- Dyne Therapeutics downgraded to Neutral from Overweight at JPMorgan